Adaptive Biotechnologies Corporation has announced a new partnership with Flatiron Health. The collaboration involves integrating Adaptive's clonoSEQ® test for measurable residual disease $(MRD.AU)$ assessment in lymphoid malignancies into Flatiron's cloud-based Electronic Medical Record $(EMR)$ platform, OncoEMR®. This integration aims to streamline access to vital MRD data, enabling over 4,500 clinicians at 1,000 community-based cancer care locations across the U.S. to order and review clonoSEQ MRD testing results directly within the EMR. The partnership is intended to enhance the efficiency of testing workflows and provide real-time insights into patients' disease status, thereby empowering community oncology practices to make more informed and personalized treatment decisions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.